More on IMCR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.6 Score)

Upcoming Events

- Earnings (11/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Immunocore (NQ:IMCR)
Delayed: 32.12 +0.03 (0.09%)
Prev. Close $32.09  
Open$32.04 
52 Wk High$ 
52 Wk Low$ 
Day High$32.79 
Day Low$31.30 
P/E N/A  
EPS$ 
Volume283,252 


Oct 19, 2026 04:05 PM Mineralys Therapeutics adds two directors with pharma experience
Oct 19, 2026 04:05 PM Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Oct 15, 2026 07:00 AM Immunocore doses first patient in type 1 diabetes Phase 1 trial
Oct 15, 2026 07:00 AM Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Oct 7, 2026 11:47 AM Form SCHEDULE 13G/A Immunocore Holdings plc Filed by: FMR LLC
Sep 14, 2026 07:15 AM Form 8-K Immunocore Holdings plc For: Sep 14
Sep 14, 2026 07:01 AM Immunocore completes enrollment in Phase 3 melanoma trial
Sep 14, 2026 07:00 AM Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Sep 1, 2026 07:00 AM Immunocore to present at upcoming investor conferences
Aug 22, 2026 07:55 AM TD Cowen Assumes Immunocore Holdings (IMCR) at Buy
View All Articles

Entities mentioned with IMCR

View All Entities